Protective Effect of Boswellic Acids against Doxorubicin-Induced Hepatotoxicity: Impact on Nrf2/HO-1 Defense Pathway

Table 1

Effect of three weekly doses of doxorubicin (6 mg/kg) alone or in combination with boswellic acids (125, 250, or 500 mg/kg/day) on serum ALT and AST in mice.

Groups	ALT (unit/l)	AST (unit/l)
Saline	59.17 ± 14.39 (%CV = 24.31)	84.17 ± 17.41 (%CV = 20.68)
Doxorubicin (6 mg/kg/week)	158.83 ± 28.14^a (%CV = 17.72)	191.33 ± 45.26^a (%CV = 23.66)
Doxorubicin (6 mg/kg/week) + BAs (125 mg/kg)	110.83 ± 22.46^b (%CV = 20.27)	158.17 ± 27.59^b (%CV = 17.44)
Doxorubicin (6 mg/kg/week) + BAs (250 mg/kg)	91.33 ± 8.71^b (%CV = 9.54)	129.33 ± 18.03^b (%CV = 13.94)
Doxorubicin (6 mg/kg/week) + BAs (500 mg/kg)	72.2 ± 12.81^bc (%CV = 17.79)	125.67 ± 10.78^bc (%CV = 8.58)

Mice were injected with doxorubicin (DOX, 18 mg/kg i.p.) in combination with boswellic acids (BAs, 125, 250, or 500 mg/kg). Data are mean ± SD, and analysis was done by one-way ANOVA followed by Tukey’s post hoc test. ^aCompared to the saline group. ^bCompared to the DOX group. ^cCompared to the doxorubicin + BAs (125 mg/kg) group. value < 0.05.